Shooting Cancer Highlights – UGT1A1 & DPYD: Safer chemotherapy starts with genotyping
DPYD Genotyping in Fluoropyrimidine Therapy: Reducing Toxicity, Improving Outcome Fluoropyrimidines such as 5-fluorouracil (5-FU), capecitabine, and tegafur are widely used in oncology, treating over 3.5 million patients annually—with 600,000 in Europe alone. Despite their effectiveness, these drugs carry a significant risk of toxicity: 10–40% of patients develop severe side effects (Grade 3–4) requiring hospitalisation and […]
Advancing Precision Medicine: Preventing ADRs with Pharmacogenomic Panel Testing
Drug response is highly variable between individuals. This interindividual variability response to medication, which contributes to adverse drug reactions (ADRs), is mainly due to interaction between genetic variants and medications (1). ADRs are estimated to be between the fourth and sixth most common cause of death worldwide, entering in the list of other prevalent causes […]
Diatech Pharmacogenetics will attend the SEAP-IAP 2025 Congess
We are excited to share that Diatech Pharmacogenetics will be attending the 32nd National Congress of SEAP-IAP From May 23 to May 25 2025 Palacio de Congresos y Auditorio Kursaal, San Sebastiàn, Spain
Diatech Pharmacogenetics will exhibit at Medlab-Middle East from February 3 to 6 in Dubai
Diatech Pharmacogenetics will exhibit at Medlab, a landmark event in the Middle East highlighting cutting-edge advances and sustainable practices in laboratory medicine. Visit us at stand Z6C51 from 3 to 6 February 2025!